Journal of Clinical Oncology, Vol 23, No 22 (August 1), 2005: pp. 5188-5197
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.05.013
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Thrombospondin-1–Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Cancer
Ronald Hoekstra,
Filip Y.F.L. de Vos,
Ferry A.L.M. Eskens,
Jourik A. Gietema,
Ate van der Gaast,
Harry J.M. Groen,
Raymond A. Knight,
Robert A. Carr,
Rod A. Humerickhouse,
Jaap Verweij,
Elisabeth G.E. de Vries
From the Department of Medical Oncology, Erasmus MC, University Medical Center, Rotterdam; Department of Medical Oncology and Pulmonology, University Hospital Groningen, Groningen, the Netherlands; and Abbott Laboratories, Chicago, IL.
Address reprint requests to Ronald Hoekstra, MD, Department of Internal Medicine, Twenteborg Hospital, PO Box 7600, 7600 SZ, Almelo, the Netherlands; e-mail: r.hoekstra{at}zgt.nl
PURPOSE: ABT-510 is an angiogenesis inhibitor derived from thrombospondin-1, a naturally occurring inhibitor of angiogenesis. We investigated ABT-510, which was administered subcutaneously in patients with advanced solid malignancies, to assess safety, pharmacokinetics, and serum markers of angiogenesis.
PATIENTS AND METHODS: ABT-510 was administered subcutaneously as a continuous infusion (100 mg/24 h) and bolus injections (100, 200, and 260 mg once daily; 50 and 100 mg twice daily) in 28-day cycles.
RESULTS: Thirty-nine patients received a total of 144 treatment cycles. Administration by continuous infusion was hampered by the onset of painful skin infiltrates at the injection site. In the bolus injection regimens, the most common toxicities observed were mild injection-site reactions and fatigue. Maximum-tolerated dose was not defined, but 260 mg was defined as the maximum clinically practical dose. ABT-510 pharmacokinetics were linear across the dosage ranges tested, and the potential therapeutic threshold (plasma concentrations > 100 ng/mL > 3 h/d) was achieved with all dose regimens. Median serum basic fibroblast growth factor (bFGF) levels decreased from 14.1 pg/mL (range, 0.5 to 77.7 pg/mL) at baseline to 3.2 pg/mL (range, 0.2 to 29.4 pg/mL) after 56 days of treatment (P = .003). No correlations with time on study or ABT-510 dose or exposure were observed for individual changes in bFGF. Stable disease lasting for six cycles or more was seen in six patients.
CONCLUSION: ABT-510 demonstrated a favorable toxicity profile and linear and time-independent pharmacokinetics with biologically relevant plasma concentrations. The significant number of patients with prolonged stable disease and the convenient method of dosing merit further studies with this angiogenesis inhibitor.
Supported by Abbott Laboratories, Chicago, IL.
Presented in part at the 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 18-21, 2002.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
This article has been cited by other articles:
|
|
|
|
 
N. T. Fernando, M. Koch, C. Rothrock, L. K. Gollogly, P. A. D'Amore, S. Ryeom, and S. S. Yoon
Tumor Escape from Endogenous, Extracellular Matrix-Associated Angiogenesis Inhibitors by Up-Regulation of Multiple Proangiogenic Factors
Clin. Cancer Res.,
March 1, 2008;
14(5):
1529 - 1539.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ebbinghaus, M. Hussain, N. Tannir, M. Gordon, A. A. Desai, R. A. Knight, R. A. Humerickhouse, J. Qian, G. B. Gordon, and R. Figlin
Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma
Clin. Cancer Res.,
November 15, 2007;
13(22):
6689 - 6695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Zhang, J. Xu, J. Lawler, E. Terwilliger, and S. Parangi
Adeno-Associated Virus-Mediated Antiangiogenic Gene Therapy with Thrombospondin-1 Type 1 Repeats and Endostatin
Clin. Cancer Res.,
July 1, 2007;
13(13):
3968 - 3976.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Isenberg, Y. Jia, J. Fukuyama, C. H. Switzer, D. A. Wink, and D. D. Roberts
Thrombospondin-1 Inhibits Nitric Oxide Signaling via CD36 by Inhibiting Myristic Acid Uptake
J. Biol. Chem.,
May 25, 2007;
282(21):
15404 - 15415.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Yang, Y. Tian, S. Liu, R. Zeine, A. Chlenski, H. R. Salwen, J. Henkin, and S. L. Cohn
Thrombospondin-1 Peptide ABT-510 Combined with Valproic Acid Is an Effective Antiangiogenesis Strategy in Neuroblastoma
Cancer Res.,
February 15, 2007;
67(4):
1716 - 1724.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. D. Roberts, J. S. Isenberg, L. A. Ridnour, and D. A. Wink
Nitric Oxide and Its Gatekeeper Thrombospondin-1 in Tumor Angiogenesis
Clin. Cancer Res.,
February 1, 2007;
13(3):
795 - 798.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Aghi, S. D. Rabkin, and R. L. Martuza
Angiogenic Response Caused by Oncolytic Herpes Simplex Virus-Induced Reduced Thrombospondin Expression Can Be Prevented by Specific Viral Mutations or by Administering a Thrombospondin-Derived Peptide
Cancer Res.,
January 15, 2007;
67(2):
440 - 444.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Rusk, E. Cozzi, M. Stebbins, D. Vail, J. Graham, V. Valli, J. Henkin, R. Sharpee, and C. Khanna
Cooperative Activity of Cytotoxic Chemotherapy with Antiangiogenic Thrombospondin-I Peptides, ABT-526 in Pet Dogs with Relapsed Lymphoma
Clin. Cancer Res.,
December 15, 2006;
12(24):
7456 - 7464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. van Amerongen and A. Berns
TXR1-mediated thrombospondin repression: a novel mechanism of resistance to taxanes?
Genes & Dev.,
August 1, 2006;
20(15):
1975 - 1981.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Gietema, R. Hoekstra, F. Y. F. L. de Vos, D. R. A. Uges, A. van der Gaast, H. J. M. Groen, W. J. Loos, R. A. Knight, R. A. Carr, R. A. Humerickhouse, et al.
A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors
Ann. Onc.,
August 1, 2006;
17(8):
1320 - 1327.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
